On Wednesday, Grifols SA GRFS said it ended discussions with Brookfield Capital Partners (UK) Limited about a potential acquisition.This decision follows the company’s November 19 statement rejecting Brookfield’s indicative offer to acquire Grifols for 6.45 billion euros ($6.81 billion) or 10.50 euros per Class A share.Canadian fund Brookfield said it had dropped its plan to take over Spain’s Grifols due to a disagreement over the pharmaceutical company’s value, while Grifols said it concurred with the deci ...

Shares of Grifols (GRFS) lost over 7% on Wednesday after the company announced that Canada-based Brookfield Asset Management has withdrawn its plan to acquire it.Both parties likely failed to arrive at a common ground over the company's value. Last week, Grifols’ board refused to endorse Brookfield’s offer to acquire its outstanding share capital for €6.45 billion (around $6.8 billion). Per management, the valuation “significantly undervalues the company’s fundamental prospects and its long-term potential.” ...

Shares of Grifols (GRFS) lost over 8% on Tuesday after the company’s board refused to endorse Canada-based Brookfield Asset Management’s offer to acquire its outstanding share capital for €6.45 billion (around $6.8 billion).Per a regulatory filing submitted to the SEC, Grifols stated that the valuation offered by Brookfield “significantly undervalues the company’s fundamental prospects and its long-term potential.”Brookfield, along with key shareholders of Grifols, had expressed its intent for a potential t ...

Analyst's Disclosure: I/we have a beneficial long position in the shares of GRFS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advic ...

Shares of Grifols (GRFS) rose nearly 7% on Aug 21 following a report issued by Bloomberg, which stated that Canada-based Brookfield Asset Management is in talks with banks to raise funds worth €9.5 billion ($10.6 billion) in debt for its potential acquisition. Through these funds, Brookfield intends to refinance Grifols' existing debt, which includes loans and high-yield bonds. While most of the funding will be in dollars, the participating banks would be requested to commit to providing the funds 'before s ...

文章核心观点 - 公司开发了首个用于治疗和功能性治愈慢性乙型肝炎病毒(HBV)感染的重组多克隆治疗药物GIGA-2339 [1][4][5] - GIGA-2339包含超过1,000种完全人源化的重组抗HBV抗体,可复制人体自然免疫反应 [2][7] - GIGA-2339是公司重组多克隆抗体药物平台的一部分,是Grifols公司创新战略和致力于为患者和医疗专业人员提供下一代抗体药物的一部分 [3][5] 行业概况 - 目前现有疗法和疫苗仍无法治愈HBV,全球仍有2.96亿人感染HBV,每年导致超过80万人死亡 [6] - 现有药物只能抑制病毒复制,但无法显著降低病毒蛋白水平,无法彻底治愈 [6][7] 公司情况 - 公司利用行业领先的单细胞技术,开发用于治疗免疫缺陷、传染病和难治性肿瘤的创新性抗体药物 [16] - 公司的重组多克隆抗体技术平台可以捕获和重现完整的免疫细胞谱系,从而创造出首创的重组多克隆抗体治疗药物 [9] - 公司的主要股东是Grifols公司,Grifols是一家全球性的医疗保健公司,致力于改善全球人民的健康和福祉 [10][14] - Grifols专注于治疗免疫学、肝病、重症监护、肺病、血液病、神经病和传染病等多个治疗领域 [11] - Grifols拥有全球最大的血浆捐赠中心网络,在北美、欧洲、非洲、中东和中国设有超过390个捐赠中心 [12] - Grifols还提供输血医学解决方案、生命科学研究用生物原料以及医院、药房和医疗专业人员所需的工具、信息和服务 [13]

XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go straight to SCIg without initial intravenous therapy Approval, which also includes biweekly dosing, follows phase 4 study data demonstrating comparable total Ig levels when administering XEMBIFY every two weeks versus weekly The expanded label for XEMBIFY provides added flexibility and convenience for patients with primary humoral immunodeficiencies Increasing adopt ...

XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go straight to SCIg without initial intravenous therapy Approval, which also includes biweekly dosing, follows phase 4 study data demonstrating comparable total Ig levels when administering XEMBIFY every two weeks versus weekly The expanded label for XEMBIFY provides added flexibility and convenience for patients with primary humoral immunodeficiencies Increasing adopt ...

Key TakeawaysBrookfield and family member shareholders of Grifols are in talks to take the Spanish pharmaceutical firm private.The potential buyers asked the board for information so they could do due diligence.Both sides say no agreement has been reached. American depositary receipts (ADRs) of Grifols (GRFS) gained for a second day Tuesday on word Canadian investment manager Brookfield and family member shareholders are in talks to take the Spanish pharmaceutical company private.  Brookfield confirmed Mond ...

Grifols (NASDAQ:GRFS) stock is jumping on Monday after investors learned that the founding family of the company is considering a takeover offer that would see it go private. The Grifols family is working alongside Brookfield on an offer that would result in a takeover of the business. It's worth pointing out that they currently hold a 30% stake in GRFS shares. The board of directors at Grifols is considering the preliminary offer made by the Canadian fund and the Grifols family. If all goes well, this will ...